Song Mu
About Song Mu
Song Mu is the Head of Clinical Pharmacology at BeiGene in Fort Lee, NJ, with over 15 years of experience in clinical pharmacology and pharmacometrics.
Company
Song Mu is currently working at BeiGene as the Head of Clinical Pharmacology in Fort Lee, NJ. BeiGene is a global biotechnology company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Title
Song Mu holds the title of Head of Clinical Pharmacology at BeiGene. In this role, Mu leads the clinical pharmacology efforts, contributing to the development of new drugs with a focus on improving therapeutic outcomes for cancer patients.
Education and Expertise
Song Mu earned a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University of Nebraska Medical Center, studying from 1996 to 2001. Mu also holds a Bachelor’s Degree in Chemical Engineering from the University of Florida. With over 15 years of industry experience, Mu has expertise in clinical pharmacology and pharmacometrics, specifically in biologics and small molecules for therapeutic areas including oncology, CNS, virology, and inflammation.
Professional Background
Prior to joining BeiGene in January 2016, Song Mu held several key positions in leading pharmaceutical companies. Mu worked as Sr. Director / Clinical Pharmacology Lead at Pfizer for 10 months in 2011. At Novartis, Mu served as Principal Fellow Oncology Clinical Pharmacology from 2011 to 2016 and as Sr. Principal Biostatistician from 2005 to 2007. Mu also worked at Roche as Disease Area Modeling & Simulation Expert - Oncology from 2007 to 2011, and at Eli Lilly and Company as a Research Scientist from 2001 to 2005.
Industry Experience
Song Mu has extensive experience in the pharmaceutical industry, with a focus on clinical pharmacology and pharmacometrics. Mu has worked on both biologics and small molecules across various therapeutic areas, including oncology, CNS, virology, and inflammation. Mu's background includes participating in regulatory filings from Investigational New Drug (IND) applications to New Drug Applications (NDA), as well as interacting with regulatory authorities in the US and internationally.